CN1192141A - 抑制黑素瘤的方法 - Google Patents
抑制黑素瘤的方法 Download PDFInfo
- Publication number
- CN1192141A CN1192141A CN96195876A CN96195876A CN1192141A CN 1192141 A CN1192141 A CN 1192141A CN 96195876 A CN96195876 A CN 96195876A CN 96195876 A CN96195876 A CN 96195876A CN 1192141 A CN1192141 A CN 1192141A
- Authority
- CN
- China
- Prior art keywords
- chemical compound
- melanoma
- acid
- preparation
- raloxifene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000001441 melanoma Diseases 0.000 title claims abstract description 22
- 238000000034 method Methods 0.000 title claims abstract description 13
- 230000002401 inhibitory effect Effects 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 29
- 150000003839 salts Chemical class 0.000 claims abstract description 16
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims abstract description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 7
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims abstract description 4
- 239000012453 solvate Substances 0.000 claims abstract description 4
- 239000003112 inhibitor Substances 0.000 claims description 7
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims description 6
- -1 hexa-methylene ammonia Chemical compound 0.000 claims description 6
- 229960003901 dacarbazine Drugs 0.000 claims description 5
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims description 2
- 229910021529 ammonia Inorganic materials 0.000 claims description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 2
- 229960005243 carmustine Drugs 0.000 claims description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 2
- 229960004316 cisplatin Drugs 0.000 claims description 2
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 abstract description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 16
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 15
- 229960004622 raloxifene Drugs 0.000 description 15
- 229920002472 Starch Polymers 0.000 description 14
- 239000008107 starch Substances 0.000 description 14
- 235000019698 starch Nutrition 0.000 description 14
- 239000002775 capsule Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 9
- 229940011871 estrogen Drugs 0.000 description 8
- 239000000262 estrogen Substances 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 239000012530 fluid Substances 0.000 description 5
- 229920001296 polysiloxane Polymers 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- FCEHBMOGCRZNNI-UHFFFAOYSA-N thianaphthalene Natural products C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 4
- 239000003513 alkali Substances 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 4
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 239000012531 culture fluid Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000000328 estrogen antagonist Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 235000013599 spices Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000007916 tablet composition Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical class OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- OFJWFSNDPCAWDK-UHFFFAOYSA-N 2-phenylbutyric acid Chemical class CCC(C(O)=O)C1=CC=CC=C1 OFJWFSNDPCAWDK-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical class CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 1
- PXACTUVBBMDKRW-UHFFFAOYSA-M 4-bromobenzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=C(Br)C=C1 PXACTUVBBMDKRW-UHFFFAOYSA-M 0.000 description 1
- HOSGXJWQVBHGLT-UHFFFAOYSA-N 6-hydroxy-3,4-dihydro-1h-quinolin-2-one Chemical group N1C(=O)CCC2=CC(O)=CC=C21 HOSGXJWQVBHGLT-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027145 Melanocytic naevus Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 208000007256 Nevus Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- ZZXDRXVIRVJQBT-UHFFFAOYSA-M Xylenesulfonate Chemical compound CC1=CC=CC(S([O-])(=O)=O)=C1C ZZXDRXVIRVJQBT-UHFFFAOYSA-M 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- CXBNMPMLFONTPO-UHFFFAOYSA-N acetic benzoic anhydride Chemical class CC(=O)OC(=O)C1=CC=CC=C1 CXBNMPMLFONTPO-UHFFFAOYSA-N 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N beta-monoglyceryl stearate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 150000007516 brønsted-lowry acids Chemical class 0.000 description 1
- 150000007528 brønsted-lowry bases Chemical class 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- JOYKCMAPFCSKNO-UHFFFAOYSA-N chloro benzenesulfonate Chemical compound ClOS(=O)(=O)C1=CC=CC=C1 JOYKCMAPFCSKNO-UHFFFAOYSA-N 0.000 description 1
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
- 229940114081 cinnamate Drugs 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- VFNGKCDDZUSWLR-UHFFFAOYSA-L disulfate(2-) Chemical compound [O-]S(=O)(=O)OS([O-])(=O)=O VFNGKCDDZUSWLR-UHFFFAOYSA-L 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- CEAZRRDELHUEMR-UHFFFAOYSA-N gentamicin Chemical class O1C(C(C)NC)CCC(N)C1OC1C(O)C(OC2C(C(NC)C(C)(O)CO2)O)C(N)CC1N CEAZRRDELHUEMR-UHFFFAOYSA-N 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229910000043 hydrogen iodide Inorganic materials 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- TVZISJTYELEYPI-UHFFFAOYSA-N hypodiphosphoric acid Chemical compound OP(O)(=O)P(O)(O)=O TVZISJTYELEYPI-UHFFFAOYSA-N 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical class OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- 150000005342 methoxybenzoic acids Chemical class 0.000 description 1
- 150000005451 methyl sulfates Chemical class 0.000 description 1
- 229950000081 metilsulfate Drugs 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- HVZWVEKIQMJYIK-UHFFFAOYSA-N nitryl chloride Chemical compound [O-][N+](Cl)=O HVZWVEKIQMJYIK-UHFFFAOYSA-N 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- UORVCLMRJXCDCP-UHFFFAOYSA-M propynoate Chemical compound [O-]C(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-M 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229940116351 sebacate Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical compound OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229950004288 tosilate Drugs 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940071104 xylenesulfonate Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
一种抑制黑素瘤的方法,包括给病人单独服用有效量的通式(Ⅰ)的化合物,或单独服用适合药物的(Ⅰ)的盐或其溶剂化合物,或与一种或多种黑素瘤抑制剂一起服用。(Ⅰ)中R1和R3为独立H,-CH3,(a)或(b),(b)中Ar为选择性取代苯基,R2选自吡咯烷、六亚甲基氨和哌啶子基之一。
Description
发明背景
黑素瘤是一种主要位于皮肤表层的黑素细胞恶性瘤。黑素瘤主要发生在成人身上,一般由良性带颜色的痣恶化而成。任何面积增大,颜色变化或发痒等症状都预示着可能发生了恶性变化。黑素瘤引起的死亡一般约占所有癌症死亡中的1%。除在妇女中的肺癌外,黑素瘤的发病速度较其它瘤快。
黑素瘤的最大危险是其病毒通过淋巴管和血液循环转移到人体深层部位。人体的任何器官都可能被转移上,主要是转移到肺和肝上。尽管采用深切技术有时能令患者存活一段时间,但已转移到深层部位的黑素瘤很难用一般的治疗方法治愈。长期以来,黑素瘤病人成了探索新的化学疗法或改进生物技术疗法的临床试验者。
目前,经过近20年的试验,Dacarbazine(DTIC)被FDA认证为治疗黑素瘤的唯一制剂,组合使用化疗制剂,疗效并不比单独使用Dacarbazine疗效好。但只有15~25%的患者用Dacarbazine后有反应,且仅有5%的人治愈。因此有必要寻找更有效的治疗方式及另外的黑素瘤抑制剂。
发明概述
本发明提供了抑制黑素瘤的方法,该方法包括给病人单独服用有效量的通式(I)的化合物,或其药用盐或其溶剂化物,或与一种或多种黑素瘤抑制剂一起服用。式(I)中R1和R2为独立H,-CH3,
或
其中Ar为任选取代的苯基;R2选自吡咯烷、六亚甲基氨和哌啶子基。
发明详述
本发明涉及发现了有抑制黑素瘤作用的2-苯基-3-芳酰基苯并噻吩(苯并噻吩类),其通式为(I)。
本发明提供了有效抑制黑素瘤的方法:给病人单独服用有效量的通式I的化合物,或其药用盐或其溶剂化物,或与一种或多种黑素瘤抑制剂一起服用。
“抑制”一词本意包含阻止、预防、限制、减慢、停止或逆转等,本发明中其意既包含药物治疗,又包含适当的预防作用。
本发明中raloxifene是化合物I的盐酸盐,R1和R3均为H,R2为1-哌啶基,它是一个核调节分子。已证明raloxifene结合在雌激素受体上,其作用是抗雌激素,因为它能阻碍雌激素激活子宫,诱发乳腺癌。事实上,在某些细胞中raloxifene确实阻碍了雌激素发挥作用,但在其它细胞中,雌激素能激活的基因,它也能激活,显示出与雌激素相同的药学特性,如治疗骨质疏松、高血脂等。因此,raloxifene既有抗雌激素的性质,又有主动剂-拮抗剂的性质。raloxifene表现出与雌激素不同的特性,现在被认为是raloxifene-雌激素受体络合物激活和/或抑制的基因,与雌激素-雌激素受体激活和/或抑制的基因不同。所以,尽管raloxifene与雌激素利用和竞争相同的受体,但二者对基因控制的药学结果却是难以预测,彼此也不相同。
一般该化合物加入赋形剂、稀释剂或载体,压缩成片剂,或酏剂或配制成溶液,以便患者口服,或肌肉或静脉注射。该化合物可穿透皮肤,因而可制成缓释剂等形式。
合成本发明中的化合物可参阅下列美国专利,专利号为:4133814,4418068,4380635。一般以具有一个6-羟基和一个2-(4-羟基苯基)的苯并[b]噻吩为原料,经保护性酰化,去保护得到通式1的化合物。上面提到的美国专利提供了合成这些化合物的实例。选择性取代的苯基包括苯基和一重或双重取代的苯基,取代基分别为C1-C6烷基,C1-C4烷氧基,羟基、硝基、氯、氟或三(氯或氟)甲基。
本发明方法中的化合物与大量的有机和无机酸及碱反应,形成适合药用的酸和碱加成盐,及生理上可用的盐,它们常用在药物化学中。典型使用的无机酸包括盐酸、氢溴酸、碘化氢、硝酸、硫酸、磷酸、连二磷酸等、所用有机酸有脂肪族单羧酸、二羧酸、苯基取代的链烷酸、羟基烷酸和羟基链烷双酸、芳香酸、脂肪族磺酸及芳香族磺酸。适合药用的盐包括乙酸盐、苯乙酸盐、三氟乙酸盐、丙烯酸盐、抗坏血酸盐、苯甲酸盐、氯苯甲酸盐、二硝基苯甲酸盐、羟基苯甲酸盐、甲氧基苯甲酸盐、甲基苯甲酸盐、O-乙酰基苯甲酸盐、2-萘苯甲酸盐、溴化物、异丁酸盐、苯基丁酸盐、β-羟基丁酸盐、丁炔-1,4-二酸盐、己炔-1,4-二酸盐、癸酸盐、辛酸盐、氯化物、肉桂酸盐、柠檬酸盐、甲酸盐、延胡索酸盐、乙醇酸盐、庚酸盐、脲酸盐、乳酸盐、苹果酸盐、马来酸盐、羟基马来酸盐、丙二酸盐、扁桃酸盐、甲磺酸盐、烟酸盐、异烟酸盐、硝酸盐,苯酸盐、邻苯二甲酸盐、四邻苯二甲酸盐、磷酸盐、磷酸氢盐、磷酸二氢盐、偏磷酸盐、焦磷酸盐、丙炔酸盐、丙酸盐、苯丙酸盐、水扬酸盐、癸二酸盐、琥珀酸盐、辛二酸盐、硫酸盐、硫酸氢盐、焦硫酸盐、亚硫酸盐、亚硫酸氢盐、磺酸盐、苯磺酸盐、对溴苯磺酸盐、氯代苯磺酸盐、乙基磺酸盐、2-羟乙基磺酸盐、甲基磺酸盐、1-萘磺酸盐、2-萘磺酸盐、对甲苯磺酸盐、二甲苯磺酸盐、酒石酸盐等。最好是用盐酸盐。
适合药用的酸及盐主要由通式I的化合物与等量或过量的酸反应而得。反应物一般置于共溶溶剂,如乙醚或苯中混合。约1小时至10天内产物盐从溶液中沉淀出来,过滤分离之或用常规方法除去溶剂,将盐分离出来。
合成盐常用的碱有:氢氧化铵、碱金属及碱土金属的氢氧化物、碳酸盐及伯、仲、叔脂肪族胺类、脂肪族二胺类。主要用的碱有:氢氧化铵、碳酸钾、甲胺、二乙胺、乙二胺及环己胺。
适于药用的盐的溶解性比其母体化合物的溶解性好,因而更适合于配制成液体或乳剂。
配制药方已有成熟的技术。例如化合物与普通的赋形剂、稀释剂或载体可制成片剂、胶囊、悬浮液、粉末等。适合于这类制剂的赋形剂、稀释剂及载体包括:填料和增容剂,如淀粉、糖、甘露糖醇及硅衍生物;粘合剂如羧甲基纤维素及其它纤维素衍生物,如藻酸盐、明胶及聚乙烯吡咯烷酮;润湿剂如甘油;粉碎剂如碳酸钙和碳酸氢钠;溶解抑制剂如石蜡;加速吸收剂如季铵盐化合物;表面活性剂如十六烷醇、硬脂酸甘油单酯;吸附载体如高岭土和膨润土;润滑剂如滑石、硬脂酸钙、硬脂酸镁和固态聚乙烯醇。
这些化合物也可配制成酏剂,或方便的口服液,或适于非肠道使用的溶液,如肌肉,皮下或静脉途径。另外,化合物也适合配成缓释片剂等。配制的制剂能在一段时间内仅在或优先在肠道的特定部位释放活性组分。包膜、外壳、保护基质可用聚合物材料或蜡做成。
本发明介绍了利用通式I的化合物抑制黑素瘤,抑制方式和特殊剂量由医生根据病人病情的严重程度,服用方式和其它因素来决定。一般来说,适用而有效的日剂量约为0.1至1000毫克,常用量为50至200毫克。病人每天服用一至三次,若需要可增加次数,这样可在一段时间内充分有效地抑制黑素瘤。本发明还包括通式I的化合物与一种或多种黑素瘤抑制剂一起服用。这类抑制剂包括Cisplatin、Dacarbazine和亚硝基脲氮芥。
通式I的化合物常以酸加成盐的形式服用,如同惯常服用带碱性基团如哌啶环的药。那样口服也有好处。为此口服剂量如下:
制剂
下列制剂中的“活性组分”指通式I的化合物。制剂1:胶囊
利用下面的制剂制成硬胶囊:组分 量(毫克/囊)活性组分 0.1-1000淀粉NF 0-650淀粉流动性粉末 0-650硅酮流体350厘沲 0-15将各组分混合,过45目美国筛,填充进硬胶囊。含raloxifene的制剂实例如下:制剂2:raloxifene胶囊组分 量(毫克/囊)raloxifene 1淀粉NF 112淀粉流动性粉末 225.3硅酮流体350厘沲 1.7制剂3:raloxifene胶囊组分 量(毫克/囊)raloxifene 5淀粉NF 108淀粉流动性粉末 225.3硅酮流体350厘沲 1.7制剂4:raloxifene胶囊组分 量(毫克/囊)raloxifene 10淀粉NF 103淀粉流动性粉末 225.3硅酮流体350厘沲 1.7制剂5:raloxifene胶囊组分 量(毫克/囊)raloxifene 50淀粉NF 150淀粉流动性粉末 397硅酮流体350厘沲 3.0上面的制剂可根据合理的变化作调整。用下列组分配制的片剂制剂如下:制剂6:片剂组分 量(毫克/片)活性组分 0.1-1000纤维素微晶 0-650二氧化硅 0-650硬脂酸 0-15
各组分混合后压缩成片剂。另一含0.1至1000毫克活性组分的片剂制剂如下:制剂7:片剂组分 量(毫克/片)活性组分 0.1-1000淀粉 45纤维素微晶 35聚乙烯吡咯烷酮(10%的水溶液) 4羧甲基纤维素钠 4.5硬脂酸镁 0.5滑石 1
活性组分、淀粉和纤维素过45目美国筛,混合均匀。聚乙烯吡咯烷酮溶液与上述粉末混合,过14目美国筛,得到的粒剂在50~60℃烘干后过18目美国筛。羧甲基纤维素钠、淀粉、硬脂酸镁和滑石混合,过60目美国筛后与粒剂混合,在片剂机上被压制成片剂。
每5毫升含0.1至1000毫克药剂的悬浮液制剂如下:制剂8:悬浮液组分 量(毫克/5毫升)活性组分 0.1-1000毫克羧甲基纤维素钠 50毫克糖浆 1.25毫克苯甲酸溶液 0.10毫升香料 适量颜料 适量纯净水 5毫升
活性组分过45目美国筛,与羧甲基纤维素钠及糖浆混合成糊状.苯甲酸溶液、香料及颜料用少许水稀释,加入到上述糊状物中,边加边搅加入足量的水定容。
试验
用细胞群繁殖法试验通式I的化合物的活性。在试验通式I的化合物短时间曝露在黑素瘤细胞上产生的作用时,将黑素瘤细胞的单细胞悬浮液,以每培养皿20000个细胞,培育到60毫米组织培养皿中(Corning,Corning NY),允许它们接触2至4小时。将化合物加入培养皿中,孵育1小时,然后用磷酸盐缓冲盐水(Sigma Chemical Co.,St.Louis,MO)清洗三次,通过受胰蛋白作用收集细胞,再洗一次以除去药物,重新悬浮到5毫升含0.3%琼脂液的全培养液中(Difco,Detroit,MI)。悬浮液混合均匀,等分成三份,以每培养皿1毫升取样到预制的培养皿中,底层有固化的1%琼脂糖。室温下固化,并在37℃、增湿5%二氧化碳的条件下孵育。5天以后对连续细胞线,或7至14天以后对初级细胞,计数出大于125微摩尔/升的细胞群。
在试验通式I的化合物持续曝露在黑素瘤细胞上产生的作用时,以每毫升4000个细胞,将黑素瘤细胞悬浮于0.3%琼脂液中(Difco,Detroit,MI),从中取样加入到含通式I的化合物和全培养液的试管里,如RPMI1640培养液(Irving Scientific,Santa Ana,CA)含10%胎牛血清(Hyclone,Logan,UT)、50微克/毫升庆大霉素(Gemini Bio-Products,Calabasas,CA)、2毫摩尔/升L-谷氨酰胺、10纳摩尔/升氢化可的松、5微克/毫升胰岛素、5微克/毫升转铁球蛋白、10纳摩尔/升雌甾二醇和5纳克/毫升硒(Sigma Chemical Co.,St.Louis,MO),悬浮液混合均匀,等分成三份,以每培养皿1毫升取样至预制的培养皿中,底层含固化的1%琼脂糖。室温下固化,在37℃、增湿5%二氧化碳的条件下孵育。5天以后对连续细胞线,或7至14天以后对初级细胞,计数出大于125微摩尔/升的细胞群。
上述试验中至少有一个试验表明化合物的活性可用于抑制黑素瘤。
Claims (5)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/466,673 | 1995-06-06 | ||
US08/466,673 US5843974A (en) | 1995-06-06 | 1995-06-06 | Methods of inhibiting melanoma using Benzothiophenes as cytotoxic agents per se |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1192141A true CN1192141A (zh) | 1998-09-02 |
Family
ID=23852667
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN96195876A Pending CN1192141A (zh) | 1995-06-06 | 1996-06-06 | 抑制黑素瘤的方法 |
Country Status (16)
Country | Link |
---|---|
US (1) | US5843974A (zh) |
EP (1) | EP0747053A3 (zh) |
JP (1) | JPH11507371A (zh) |
KR (1) | KR19990022364A (zh) |
CN (1) | CN1192141A (zh) |
AU (1) | AU702716B2 (zh) |
CA (1) | CA2223157A1 (zh) |
CZ (1) | CZ383197A3 (zh) |
EA (1) | EA000680B1 (zh) |
HU (1) | HUP9901093A3 (zh) |
IL (1) | IL118574A0 (zh) |
MX (1) | MX9709466A (zh) |
NO (1) | NO975580L (zh) |
PL (1) | PL323924A1 (zh) |
WO (1) | WO1996039135A1 (zh) |
ZA (1) | ZA964682B (zh) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6228850B1 (en) * | 1997-09-30 | 2001-05-08 | Dabur Research Foundation | Antiangiogenic activity of betulinic acid and its derivatives |
US6670345B1 (en) | 1997-09-30 | 2003-12-30 | Dabur Research Foundation | Betulinic acid derivatives for inhabiting cancer growth and process for the manufacture of betulinic acid |
US6048847A (en) * | 1997-09-30 | 2000-04-11 | Dabur Research Foundation | Use of betulinic acid and its derivatives for inhibiting cancer growth and a method of monitoring this |
CA2372720C (en) | 1999-05-04 | 2007-09-11 | John Antony Kanis | Androgen glycosides and androgenic activity thereof |
JP5650367B2 (ja) * | 2004-02-27 | 2015-01-07 | アンティセンス ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 医薬組成物 |
CN101389345A (zh) * | 2004-03-19 | 2009-03-18 | 宾州研究基金会 | 治疗黑素瘤的组合方法和组合物 |
CN104780976B (zh) | 2012-08-13 | 2019-01-01 | 洛克菲勒大学 | 治疗和诊断黑素瘤 |
CA2939120A1 (en) | 2014-01-10 | 2015-07-16 | Rgenix, Inc. | Lxr agonists and uses thereof |
US9758786B2 (en) | 2016-02-09 | 2017-09-12 | Autotelic, Llc | Compositions and methods for treating pancreatic cancer |
AU2018373028A1 (en) | 2017-11-21 | 2020-04-30 | Inspirna, Inc. | Polymorphs and uses thereof |
CN114728875A (zh) | 2019-12-13 | 2022-07-08 | 因思博纳公司 | 金属盐及其用途 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4133814A (en) * | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
US4380635A (en) * | 1981-04-03 | 1983-04-19 | Eli Lilly And Company | Synthesis of acylated benzothiophenes |
US4418068A (en) * | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
US4656187A (en) * | 1981-08-03 | 1987-04-07 | Eli Lilly And Company | Treatment of mammary cancer |
US5075321A (en) * | 1987-03-24 | 1991-12-24 | University Of Pennsylvania | Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes |
TW366342B (en) * | 1992-07-28 | 1999-08-11 | Lilly Co Eli | The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss |
US5457113A (en) * | 1993-10-15 | 1995-10-10 | Eli Lilly And Company | Methods for inhibiting vascular smooth muscle cell proliferation and restinosis |
UA32427C2 (uk) * | 1993-10-15 | 2000-12-15 | Елі Ліллі Енд Компані | Застосування бензотіофенів або їх фармацевтично прийнятних солей або сольватів для інгібування ангіогенезу і/або ангіогенних захворювань |
ATE220323T1 (de) * | 1993-10-15 | 2002-07-15 | Lilly Co Eli | Methode zur behandlung von resistenten neoplasmen |
US5476862A (en) * | 1993-12-21 | 1995-12-19 | Eli Lilly And Company | Methods of increasing thrombomodulin expression |
US5622975A (en) * | 1995-06-01 | 1997-04-22 | Eli Lilly And Company | Methods for inhibiting vascular smooth muscle cell migration |
US5726168A (en) * | 1995-10-12 | 1998-03-10 | Eli Lilly And Company | Lipophilic benzothiophenes |
US5780497A (en) * | 1996-04-19 | 1998-07-14 | American Home Products Corporation | 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents |
-
1995
- 1995-06-06 US US08/466,673 patent/US5843974A/en not_active Expired - Fee Related
-
1996
- 1996-05-30 EP EP96303878A patent/EP0747053A3/en not_active Withdrawn
- 1996-06-05 IL IL11857496A patent/IL118574A0/xx unknown
- 1996-06-05 ZA ZA9604682A patent/ZA964682B/xx unknown
- 1996-06-06 CN CN96195876A patent/CN1192141A/zh active Pending
- 1996-06-06 PL PL96323924A patent/PL323924A1/xx unknown
- 1996-06-06 EA EA199800015A patent/EA000680B1/ru not_active IP Right Cessation
- 1996-06-06 CZ CZ973831A patent/CZ383197A3/cs unknown
- 1996-06-06 MX MX9709466A patent/MX9709466A/es unknown
- 1996-06-06 JP JP9502042A patent/JPH11507371A/ja active Pending
- 1996-06-06 AU AU61090/96A patent/AU702716B2/en not_active Ceased
- 1996-06-06 CA CA002223157A patent/CA2223157A1/en not_active Abandoned
- 1996-06-06 KR KR1019970708844A patent/KR19990022364A/ko not_active Application Discontinuation
- 1996-06-06 HU HU9901093A patent/HUP9901093A3/hu unknown
- 1996-06-06 WO PCT/US1996/009839 patent/WO1996039135A1/en not_active Application Discontinuation
-
1997
- 1997-12-03 NO NO975580A patent/NO975580L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
NO975580D0 (no) | 1997-12-03 |
CA2223157A1 (en) | 1996-12-12 |
MX9709466A (es) | 1998-02-28 |
HUP9901093A3 (en) | 2000-02-28 |
JPH11507371A (ja) | 1999-06-29 |
IL118574A0 (en) | 1996-10-16 |
EP0747053A2 (en) | 1996-12-11 |
KR19990022364A (ko) | 1999-03-25 |
HUP9901093A2 (hu) | 1999-10-28 |
CZ383197A3 (cs) | 1998-07-15 |
PL323924A1 (en) | 1998-04-27 |
EA199800015A1 (ru) | 1998-06-25 |
AU702716B2 (en) | 1999-03-04 |
ZA964682B (en) | 1997-12-05 |
EP0747053A3 (en) | 1997-01-29 |
EA000680B1 (ru) | 2000-02-28 |
NO975580L (no) | 1997-12-03 |
AU6109096A (en) | 1996-12-24 |
WO1996039135A1 (en) | 1996-12-12 |
US5843974A (en) | 1998-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR19980702079A (ko) | 세포-세포 접착의 억제 방법 | |
CN1095663C (zh) | 抑制低密度脂蛋白氧化和动脉粥样硬化的方法 | |
CN1192141A (zh) | 抑制黑素瘤的方法 | |
CN1108093A (zh) | 抑制血管舒缩症状和护理有关绝经后综合征心理障碍的方法 | |
JPH07242546A (ja) | ミエロペルオキシダーゼ活性の阻害に適した医薬組成物 | |
CN1107707A (zh) | 抑制体重增加或诱发体重减轻的方法 | |
MXPA97009466A (en) | Medicine to inhibit the melan | |
CN1169116A (zh) | 抑制环境雌激素的方法 | |
CN110433160A (zh) | 一种治疗肝纤维化的化合物及其应用 | |
CZ106098A3 (cs) | Použití benzothiofenu k přípravě farmaceutického prostředku k inhibici inhibitoru 1 plasminogenového aktivátoru | |
AU688112B2 (en) | Methods of inhibiting endometrial cancer | |
CZ83997A3 (en) | Inhibition methods of endometrial mitoses | |
RU2176503C2 (ru) | Способы снижения уровней кальция в сыворотке | |
EP0729755A2 (en) | 2-Phenyl-3-aroylbenziothiophenen for inhibiting ovarian cancer | |
KR100522646B1 (ko) | 유방암의예방방법 | |
CZ52297A3 (en) | Pharmaceutical preparation for inhibiting primary endometrial hyperplasia | |
KR19990082055A (ko) | 근육건막성 섬유종증(유건종)의 억제 방법 | |
CN1209745A (zh) | 抑制结肠肿瘤的方法 | |
MXPA97006520A (en) | Methods to inhibit the ova cancer | |
MXPA97005697A (en) | Methods to reduce your calcium levels | |
CN1169678A (zh) | 防治原发性子宫内膜增生的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |